Hoarding, gouging worsen drug prices after GSK's exit

Hoarding, gouging worsen drug prices after GSK’s exit

Drug prices remain high as tariff waivers drag

A combination of hoarding and price gouging has sent drug prices to record highs following the exit of GlaxoSmithKline (GSK) from Nigeria. While the country’s devalued currency and high tariffs on pharmaceutical imports have already worsened drug pricing woes, middlemen have capitalised on the

```

Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```